G/TBT/N/CAN/465
5 August 2015 
(15-4028)  Page: 1/2
Committee on Technical Barriers to Trade  Original: English/French
 
  NOTIFICATION 
The following notification is being circulated in accordance with Article 10.6 
 
1. Notifying Member: CANADA 
If applicable, name of local government involved (Article 3.2 and 7.2):  
2. Agency responsible: Health Canada 
Name and address (including telephon e and fax numbers, email and website 
addresses, if available) of agency or authority designated to handle comments 
regarding the notification shall be indicated if different from above : 
Canada's Notification Authority and Enquiry Point 
Foreign Affairs, Trade and Development Canada 
Technical Barriers and Regulations Division (TIB) 111 Sussex Drive Ottawa, ON K1A 0G2 
Canada 
Tel: (343) 203-4273  Fax: (613) 943-0346 
E-mail: enquirypoint@international.gc.ca   
3. Notified under Article 2.9.2 [X], 2.10 .1 [ ], 5.6.2 [ ], 5.7.1 [ ], other: 
4. Products covered (HS or CCCN where applic able, otherwise national tariff heading. 
ICS numbers may be provided in addition, where applicable): 2C-phenethylamines 
and their salts, derivatives, isomers and salts of derivatives and isomers (ICS: 11.120) 
5. Title, number of pages and language(s) of the notified document: Notice to 
Interested Parties – Proposed Order amending Schedule III to the Controlled Drugs and 
Substances Act (CDSA) and Regulations Amending the Schedule to Part J of the Food and 
Drug Regulations (FDR) to include 2C-phenethylamines and their salts, derivatives, isomers and salts of derivatives and isomers (2 pages, available in English and French) 
6. Description of content: The United Nations Commission on Narcotic Drugs voted in 
favour of scheduling three 2C-phenethylamines derivatives, 25B-NBOMe, 25C-NBOMe, and 
25I-NBOMe, under Schedule I to the United Nations Convention on Psychotropic 
Substances 1971.  2C-phenethylamines are potent synthetic hallucinogens having both 
stimulant and hallucinogenic properties. Considered as "designer drugs", they are 
emerging in the market at a rapid pace. These designer drugs are readily available for sale 
on the internet as "research chemicals" and at  raves, nightclubs and head shops. Around 
the world, these products have been associated  with significant health and safety risks. 
There are no known legitimate therapeutic or industrial uses and only limited scientific and 
research uses for 2C-phenethylamines.  
This notice provides interested stakeholders with the opportunity to comment on Health 
Canada's intent to pursue amendments to Schedule III to the CDSA and the Schedule to 
Part J of the FDR to include 2C-phenethylamin es and their salts, derivatives, isomers and 
salts of derivatives and isomers. This would include 25B-NBOMe, 25C-NBOMe and 25I-NBOMe and their salts. G/TBT/N/CAN/465 
 
- 2 - 
 
  7. Objective and rationale, including the nature of urgent problems where 
applicable: Protection of human health 
8. Relevant documents: Canada Gazette , Part I, 1 August 2015, Pages 2158-2159 
(Available in English and French) 
9. Proposed date of adoption: Anticipated for spring 2016 
Proposed date of entry into force: On the date the regulations are adopted   
10. Final date for comments: 15 October 2015 
11. Texts available from: Nati onal enquiry point [X] or address, telephone and fax 
numbers and email and website addresses, if available, of other body:  
The electronic version of the notice can be downloaded at: http://www.gazette.gc.c a/rp-pr/p1/2015/2015-08 -01/pdf/g1-14931.pdf 
http://www.gazette.gc .ca/rp-pr/p1/2015/201 5-08-01/html/notice -avis-eng.php#nb4   
http://www.gazette.gc .ca/rp-pr/p1/2015/201 5-08-01/html/notice -avis-fra.php#nb4